



microRNAs as Biomarkers of Cardiovascular Diseases 2.0

Guest Editor:

Dr. Celestino Sardu

Department of Medical, Surgical,
Neurological, Metabolic and
Aging Sciences, University of
Campania "Luigi Vanvitelli",
Piazza Miraglia, 80138 Naples,
Italy

Deadline for manuscript
submissions:

closed (30 September 2023)

Message from the Guest Editor

Dear Colleagues,

microRNAs (miRs) are biomarkers of cardiovascular diseases (CDVs), which have been evaluated for diagnostic approaches and monitoring the responsiveness to medical, interventional, and surgical treatments of patients with CVDs. This has led to the initiation of many clinical trials and to the development of antago-miRs and/or mimic-miRs therapies to block and/or to promote the expression of specific miRs. This Special Issue on miRs and CVDs is therefore a particularly topical addition to the field, providing up-to-date insight into delivery of antago/mimic-miRs, safety-related issues, proof-of-principle in preclinical disease models, clinical trials in CVD patients, and approval of miR therapy-based drugs.

Dr. Celestino Sardu

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)